Pharmaceutical company, Catabasis, and charity Duchenne UK have announced a partnership to study the drug, edasalonexent, in the non-ambulatory DMD population.
Edasalonexent works by turning off an enzyme called NF-kB, which is known to be overactive in DMD. It has been shown to slow the progression of Duchenne and is currently being evaluated in a phase 3 trial in boys aged four to seven.
The new study will evaluate the safety and efficacy of the drug in non-ambulatory boys and men and will be recruiting in the UK.
Read the press release from Catabasis here.
If you have any research questions, please contact our Research Line on email@example.com